Top 20 of Bile Duct Diseases

Article title # Publications/# Citations

The cholangiopathies: disorders of biliary epithelia.

2004: NFLaRusso; KNLazaridis; MStrazzabosco;

69

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

2006: PCHarris; NFLaRusso; AIMasyuk; TVMasyuk; VETorres;

63

Endoscopic management of bile duct stones; (apples and oranges).

1984: PBCotton;

59

Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database.

2004: STFan; CMLam; CLLiu; CMLo; RTPoon; JWong; CYeung; WKYuen;

53

Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation".

1992: VJDesmet;

42

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

2004: HDenk; PFickert; AFuchsbichler; AKaser; RKrause; FLammert; CLangner; HUMarschall; ... HTilg; MTrauner; MWagner; KZatloukal; GZollner;

38

Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver.

1999: GAlpini; ABenedetti; ACaligiuri; SSGlaser; LAHolcomb; AMJezequel; GDLeSage; LMarucci; ... EPapa; JLPhinizy; RRodgers; ZTretjak;

36

Major hepatic resection. A 25-year experience.

1983: WPLongmire; HHThompson; RKTompkins;

36

Autoimmune related pancreatitis.

2002: TChiba; KOkazaki;

32

Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities.

1998: VJDesmet;

30

Foxa1 and Foxa2 regulate bile duct development in mice.

2009: KHKaestner; ZLi; NRubins; SSackett; GTuteja; PWhite;

29

Pathophysiology of cholangiopathies.

2005: LFabris; CSpirli; MStrazzabosco;

28

Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation.

1994: CACamargo; PAClavien; RCroxford; PDGreig; BLanger; GALevy;

27

The pathobiology of biliary epithelia.

2002: GAlpini; NFLaRusso; JMMcGill;

27

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

2001: GJGores; KNLazaridis; KDLindor;

26

Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study.

2003: ZBalogh; GDávid; PKüronya; LLakatos; PLLakatos; TPandur; ATollas;

25

SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video).

2007: YKChen; DKPleskow;

24

Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP.

2004: HKHa; AYKim; JSKim; KAKim; KWKim; PNKim; TKKim; JHLee; ... JKLee; MGLee; MSPark; SWPark;

23

Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.

2007: LEl Ghormli; GGloria; AWHsing; KAMcGlynn; LMellemkjaer; JHOlsen; LCSakoda; TMWelzel;

22

Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation.

1988: GJAlexander; RYCalne; PTDonaldson; FHarvey; JGO'Grady; BPortmann; SSutherland; RWilliams;

21